Avadel Pharmaceuticals Presents Results From Social Listening Analysis And Survey Of People With Narcolepsy Uncover Real-Life Challenges With Twice-Nightly Oxybate Therapy; Findings Published In 'Brain Sciences' Showed Missed Doses And Potential For Injury When Waking To Take A Second Dose Among The Key Challenges

– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges –

DUBLIN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of combined findings from a social media analysis and a survey of people with narcolepsy taking twice-nightly sodium oxybate. Results showed that these individuals report inconsistent adherence to prescribed dosing, which can lead to negative consequences in their lives. The recommended dosing for twice-nightly sodium oxybates is a first dose at bedtime and a second dose administered 2.5 to 4 hours later. The paper, titled "Understanding the Patient Experience With Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment," was published in Brain Sciences.